Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model
21(5):323-331
GSK0660 blocks the TNFα-induced upregulation of CCL8
1021/jm301859s
InChiKey: JZZFDCXSFTVOJY-UHFFFAOYSA-N
CC-930 - CAS# 899805-25-5 Catalog No.:M6544-10 higher doses than those requiredCC 930, also known as Tanzisertib, CAS No. 899805 25 5, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC 930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC 930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of